I-Mab

168 articles about I-Mab

• I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

  5/26/2022

  I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced preliminary data of its ongoing Phase 2 clinical trial (NCT04322006) with uliledlimab (also known as TJD5, or TJ004309), a differentiated CD73 antibody, and its global clinical development plan.

• I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

  5/19/2022

  I-Mab (the "Company") (Nasdaq" IMAB), today announced that it will hold a call with investors at 8 a.m. EST on May 27th to present preliminary data from an ongoing phase 2 clinical trial of its differentiated CD73 antibody uliledlimab (also known as TJD5, or TJ004309) and the global clinical development plan.

• 

  SEC Tightens Screws on Chinese Companies with Delisting Efforts

  5/6/2022

  The U.S. SEC continues to tighten the screws on Chinese companies, adding more than 80 companies to its expanding list of companies that might be dropped from U.S. stock exchanges.

• I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act

  5/5/2022

  I-Mab  today provided updates on its status under the Holding Foreign Companies Accountable Act (the "HFCAA").

• I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer

  4/28/2022

  I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced the appointments of Mr. Richard Yeh as Chief Operating Officer and Dr. John Hayslip as Chief Medical Officer.

• I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment

  3/31/2022

  I-Mab today announced that the Company's key shareholders including CBC Group (including its affiliates) and Hony Capital (collectively, the "Key Shareholders") as well as its senior management team have voluntarily entered into a 180-days lock-up period commencing from March 31, 2022.

• I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021

  3/29/2022

  I-Mab announced financial results for the 12 months ended December 31, 2021, and provided key business updates.

• I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022

  3/18/2022

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2021 before the market opens on Tuesday, March 29, 2022.

• I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

  3/9/2022

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring translational research data of enoblituzumab (also known as TJ271) and preclinical data of TJ-C64B will be presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting, to be held April 8-13, 2022.

• 

  J&J, Biopharma Turn to China for Innovative Collaborations

  3/7/2022

  China has become a leader in biotech in the last five years, especially in CAR-T therapies. Companies like Johnson & Johnson are on the prowl to acquire Chinese companies to form collaborations.

• I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer

  3/3/2022

  I-Mab today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for TJ-CD4B, a novel Claudin 18.2 x 4-1BB.

• I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs

  1/28/2022

  I-Mab announced the signing of a partnership agreement with the Hangzhou Qiantang New Area in China to manufacture its innovative drugs locally and accelerate its transition to commercialization.

• I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

  1/18/2022

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in its China phase 2 trial of lemzoparlimab in combination with the PD-1 antibody toripalimab (TUOYI®) in patients with advanced solid tumors.

• I-Mab Announces Execution of Senior Management Team Share Purchase Plan

  1/14/2022

  The execution demonstrates senior management team's tremendous confidence in the Company's innovative globally competitive pipeline and long-term growth prospects.

• I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

  1/12/2022

  I-Mab today announced that the first patient had been dosed in its China phase 2 study (NCT05145907) of efineptakin alfa.

• I-Mab Announces Senior Management Team Share Purchase Plan - Jan 06, 2022

  1/6/2022

  I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the senior management team of the Company

• I-Mab Announces Upcoming Participation at January 2022 Conferences

  12/31/2021

  I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced its participation in the following conferences in January 2022.

• I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

  12/27/2021

  I-Mab announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved I-Mab's IND submission for the initiation of a phase 2 trial in China for enoblituzumab.

• I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization

  12/20/2021

  I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced strategic leadership changes and a new governance initiative designed to facilitate its global pipeline development and accelerate its ongoing transformation towards an integrated global biopharma company.

• I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China

  12/15/2021

  I-Mab  (the "Company") (Nasdaq: IMAB), today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the IND submission for the initiation of a phase 1 clinical study of the bispecific antibody TJ-CD4B (also known as ABL111).